Shinil to agree joint R&D agreement for anti-cancer drug.

Published: 2006-03-17 06:58:00

Updated: 2006-03-17 06:58:00

Shinil pharmaceutical company announced on March 13 that the company agreed with Biorernex Inc. for the joint R&D of 'Amina-X" project, a new anti-cancer therapy after changing the name of project "BVX".

The project name change was due to the withdrawal of the exclusive use licence of the fun...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK